Evaluation of liposomal nanosystems as oncological treatment and diagnostic agents.
DOI:
https://doi.org/10.35954/SM2015.34.1.3Keywords:
Cancer Diagnostics; Nanotechnology; Breast Neoplasms; Drug Delivery SystemsAbstract
Curcumin is a natural polyphenol molecule derived from the plant Curcuma longa that exhibits anticancer, antifungal, antiviral, antioxidative, anti-inflammatory and antiploriferative properties. Curcumin is widely available in the world, is safe, inexpensive and has multiple cancer-fighting functions that justify its development as a drug for cancer treatment. However, several basic and clinical studies have elucidated its limited efficacy due to its low solubility, high metabolism rate and low bioavailability. In order to target curcumin more selectively to tumor formations and to overcome all the aforementioned disadvantages, various liposomal strategies such as "nanocarriers" for curcumin encapsulation were studied. There fore, in order to enhance the action and delivery of curcumin as an antineoplastic, a liposomal curcumin nanosystem was developed. The in vitro antitumor effect of curcumin and liposomal curcumin was evaluated in 4T1 murine mammary tumor cells and ex vivo studies were performed in a murine model of mammary tumor induced with 4T1 cells. The results obtained have been very encouraging, we have achieved the encapsulation of curcumin, with an encapsulation efficiency of 31 %. Stable liposomal formulations were obtained, which could be characterized, showing that they had a manometric size (240 nm). Both curcumin and the developed nanosystem, at the concentrations studied, were shown to be cytotoxic in murine 4T1 breast cancer cells. Therefore, the developed nanosystem has potential for the development of liposomal formulations in tumor targeting applications for imaging and oncological treatment.
Received for evaluation: January 2015
Accepted for publication: May 2015
Correspondence: Radiopharmacy Laboratory, Nuclear Research Center, Faculty of Sciences, Universidad de la Republica. Mataojo 2055, C.P. 11400, Montevideo, Uruguay. Tel: (+598)25250901/108; fax: (+598)25250895.
Contact e-mail: pcabral@cin.edu.uy
Downloads
Metrics
References
(1) Maheshwari R, Singh A, Gaddipati J, Srimal R. Multiple biological activities of curcumin: A short review. Life Sci 2006; 78(18):2081-7.
(2) Anand P, Kunnumakkara A, Newman R, Aggarwal B. Bioavailability of curcumin: Problems and promises. Mal Pharm 2007; 4(6):807-18.
(3) Lopez-Lazaro M. Anticancer and carcinogenic properties of curcumin: Considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 2008; 52(Suppl.1):103-27.
(4) Shenoy D, Amiji M. Poly(ethylene oxide)-modified poly(??-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 2005; 293(1- 2):261-70.
(5) Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et.al. Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013; 8(1):102.
(6) Fan Y, Zhang Q. Development of liposomal formulations: From concept to clinical investigations. Asian J Pharm Sci 2013; 8(2):81-87.
(7) Angius F, Floris A. Toxicology in Vitro Liposomes and MTT cell viability assay : An incompatible affair. Toxicol Vitr 2015; 29(2):314-9.
(8) Bozzuto G, Molinari A. Liposomes as nanomedical devices. lntJ Nanomedicine 2015; 2(10):975-99.
(9) Gregoriadis G, Florence A. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993; 45(1):15-28.
(10) Johnston M, Semple S, Klimuk S, Ansell S, Maurer N, Cullis P. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta 2007; 1768(5):1121-7.
(11) Noble C, Guo Z, Hayes M, Marks J, Park J, Benz C, et.al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 2009; 64(4):741-51.
(12) Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007; 4(4):297-305.
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 Nicole Lecot, Natalia Oddone, Marcelo Fernández, Juan Benech, Juan Pablo Gambini, Pablo Cabral. The author retains his copyright and assigns to the journal the right of first publication of his work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License that allows sharing the work as long as the initial publication in this journal is indicated.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
